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Summary Whether duodenal adenocarcinoma should be considered as a gastrointestinal or as a peripancreatic cancer is a matter of
debate, as is the opportunity and type of treatment. We investigated 12 such cancers for the genetic anomalies involved in the pathogenesis
of gastrointestinal malignancies, including (a) those occurring in common-type cancers - allelic losses at chromosomes 3p, 5q, 17p and 18q,
and Ki-ras and p53 alterations; and (b) those characteristic of mutator-phenotype cancers - microsatellite instability and TGF-PRII gene
mutations. We found Ki-ras and p53 mutations in five (42%) and eight cancers (67%), respectively; chromosome 3p, 5q, 17p and 18q allelic
losses in two of nine (22%), six of ten (60%), six of nine (67%) and three of ten (30%) informative cancers, respectively. Finally, three cancers
(25%) showed widespread microsatellite instability and two of them had a TGF-pRIIgene mutation. Our data suggest that duodenal cancers
may arise from either of the two known pathogenetic molecular pathways of gastric and colorectal cancers. The majority of our cases were
highly aggressive cancers with frequent chromosomal changes and p53 mutations as observed in the common-type gastrointestinal
malignancies, while widespread subtle alterations characteristic of mutator-phenotype cancers occurred in a minority, which also showed a
favourable long-term outcome.
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Sporadic cancer ofthe duodenum notoriginating from the ampulla
of Vater is a very rare disease. Yet it is the most common adeno-
carcinoma ofthe small intestine and kills 70% ofaffected patients,
with a median survival of 20 months from diagnosis (Rose et al,
1996; Sexe et al, 1996). The natural history and outcome of this
disease are poorly defined, because of its rarity and the inclusion
of the few cases described in the literature within the category of
periampullary cancers. The decision as to whether a duodenal
adenocarcinoma should be viewed as a gastrointestinal cancer or
as a peripancreatic cancer, with which the presentation is usually
confused, is unclear (Brennan, 1990; Klempnauer et al, 1995;
Rose et al, 1996). This is not a trivial question, as it also involves
controversy on the opportunity and type of surgical and/or
chemotherapeutic treatment (Brennan, 1990; Klempnauer et al,
1995; Rose et al, 1996). The study of duodenal cancers may also
help to unravel the molecular pathogenesis of cancers arising in
the periampullary area, including cancers ofthe papilla ofVater, of
the biliary tract and ofthe pancreatic head.
Two molecular pathways are known to lead to gastric and
colorectal cancer, termed the 'tumour suppressor' and the
'mutator' pathways (Perucho, 1996; Shibata, 1996). To the first
belong the more common sporadic cancers, in which the pace-
makers of tumour genesis and progression are the gross chromo-
somal changes and discrete mutations leading to the alteration of
oncogenes and tumour suppressor genes, involved in the control of
cell proliferation and death (Vogelstein et al, 1988; Kinzler and
Vogelstein, 1996; Shibata, 1996). These malignancies are charac-
terized by aneuploidy at the cytogenetic level and, atthe molecular
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level, by allelic losses in an average of at least 25% of randomly
chosen DNA sequences (Aaltonen et al, 1993). The prototypic
hereditary cancer syndrome of this pathway is familial adenoma-
tous polyposis (FAP) (Kinzler and Vogelstein, 1996; Perucho,
1996). The 'mutator pathway' has been recognized in a subset of
sporadic gastric and colorectal, but not pancreatic, cancers (Ionov
et al, 1993; Thibodeau et al, 1993; Strickler et al, 1994; Hahn et al,
1995; Konishi et al, 1996) and is a feature of cancers arising in
hereditary non-polyposis colorectal cancer (HNPCC) (Lynch et al,
1993; Konishi et al, 1996). These cancers have been defined as
USM+ (ubiquitous somatic mutations positive), RER+ (replication
error positive) or as being of the mutator phenotype. They have
defective DNA mismatch repair genes (mutator genes) (Umar et
al, 1994; Liu et al, 1995a), causing the accumulation of hundreds
of thousands of unrepaired mutations during cell replication
cycles. Such a 'DNA phenotype', that is, the existence of wide-
spread mutations throughout the genome, is easily detected by the
analysis of simple repeat motifs of 1-4 bp (microsatellites), which
are particularly prone to insertions or deletions (Liu et al, 1995b).
In addition, USM+ gastrointestinal cancers are usually euploid or
near-diploid and rarely show chromosomal losses (Strickler et al,
1994; Kinzler and Vogelstein, 1996). In these cancers, the
impaired function ofDNA repair genes also causes the mutational
activation or inactivation of functional genes (Shibata, 1996). In
particular, the tumour growth factor-p type H receptor gene (TGF-
PRII) is inactivated in almost all USM+ gastric and colonic
cancers, which escape, in this way, the TGF-p-mediated growth
control (Markowitz et al, 1995; Myeroff et al, 1995; Parsons et al,
1995; Wang et al, 1995; Shibata, 1996).
We analysed paraffin-embedded samples from 12 duodenal
cancers for the genetic anomalies involved in the genesis and
progression of malignancy of gastrointestinal cancers. These
included (a) those characteristic oftumour suppressorpathogenesis
- alterations ofKi-ras gene and p53 protein; loss ofheterozygosity
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Table 1 Clinicopathological data for the duodenal cancers, listed according to the stage of the disease
Case Sex Age Diagnosis Size Gradea Stageb Ki-ras p53 nuclear Chromosomal lossc RER+ TGF-3RII Follow-up Outcomed
(years) (cm) mutation accumulation 3p 5q 17p 18q phenotype mutation (months)
DC 2 M 50 Carcinoma 1.5 M No No No - No No Yes Yes 42 AW
DC 6 F 42 Carcinoma 2.7 M Yes No NI No No No No No 79 AW
DC 3 M 54 Carcinoma 4 M II Yes Yes No Yes No No No No 33 AW
DC 4 M 42 Carcinoma 5.5 Colloid II No No - No - - Yes Yes 25 AW
DC 5 F 45 Carcinoma 2 M II No Yes No Yes Yes No No No 66 AW
DC 1 M 56 Carcinoma 2.5 P III Yes Yes Yes Yes Yes No No No 12 DOD
DC 7 M 67 Carcinoma 10 P III No Yes No Yes NI Yes No No 13 AD
DC 8 F 62 Carcinoma 7 M IlIl Yes Yes Yes No Yes No No No 15 AD
DC 9 F 42 Carcinoma 6.5 M IlIl Yes Yes No Yes Yes Yes No No 16 DOD
DC 10 M 50 Carcinoma 5 P III No Yes No No Yes Yes No No 5 AW
DC 11 M 52 Carcinoma 1 P III No No - - - - Yes No 146 AW
DC 12 F 55 Carcinoma 4 M IlIl No Yes No Yes Yes No No No 18 DOD
aM, moderately differentiated; P, poorly differentiated. bi, confined to the duodenal wall; II, transmural involvement; III, lymph node metastases. cNI, not
informative; -, not evaluable for instability of all microsatellites analysed. dAW, alive and well; AD, alive with disease; DOD, died of disease.
(LOH) at chromosomal arms 5q21, 17pl3, 18q21 and 3pl4, which
include the loci ofAPC (adenomatous polyposis coli), p53, DCC
(deleted in colon cancer) and FHIT tumour-suppressor genes
respectively (Vogelstein et al, 1988; Kinzler and Vogelstein, 1996;
Ohta et al, 1996); and (b) those characteristic ofthe USM+ cancers
- microsatellite instability and truncating mutations in TGF-PRII
receptor gene. In two cases, for which high-molecular-weight DNA
from frozen samples was available, we could also characterizeAPC
andp53 gene mutations.
We report that sporadic cancers of duodenal non-ampullary
origin may arise from either the tumour-suppressor or the mutator
pathway, thus parallelling the molecular pathogenesis of gastric
and colorectal cancers.
MATERIALS AND METHODS
Patients and tumours
Twelve cancers of unequivocal duodenal origin were retrieved
from the files of the Department of Pathology of Verona
University, Italy. They were selected from cancers ofpatients who
underwent pancreaticoduodenectomy in the period 1985-1997.
Ampullary and all periampullary cancers for which unequivocal
duodenal origin could not be established were excluded from the
study. The patients included seven men and five women, whose
clinicopathological characteristics are reported in Table 1. All
cancers but two (DC3 and DC5) presented as ulcerated masses.
Staging was performed using the American Joint Committee on
Cancer (AJCC) criteria for small intestinal malignancies (AJCC,
1992) (Table 1). Two cancers were confined to the duodenal wall:
DC2 involved the muscularis propria and DC6 the duodenal
submucosa. Three were transmural cancers (DC3, DC4 and DC5),
with infiltration ofthe periduodenal fat and pancreas. The average
number of lymph nodes isolated from the surgical specimens was
16 (range 4-33), and nodal metastases were present in seven
cancers. All patients had a negative personal and familial history
for cancer, including FAR
In all cases, cancer cell-rich areas and matched normal mucosa
were isolated from formalin-fixed paraffin-embedded blocks, and
DNA was extracted as described (Achille et al, 1995). In cases
DC1 and DC2, frozen samples were also available and were
enriched to a neoplastic cellularity of more than 70% by cryostat
dissection (Achille et al, 1996a). In these two cases, high-
molecular-weight DNA was prepared by standard methods from
80 6-jim cryostatic sections, the cell composition of the sample
being ascertained every 20 sections, and normal DNA was obtained
from frozen strips ofnormal duodenal mucosa ofeach patient.
Molecular analysis
All cases were studied for mutations of Ki-ras and TGF-PR1I
genes, allelic losses at chromosomes 3p, 5q, 17p and 18q using
polymerase chain reaction (PCR)-based methods, as well as for
p53 protein nuclear accumulation using immunohistochemistry.
Mutations of APC and p53 genes were only analysed in the two
cases with available high-molecular-weight DNA from frozen
tissues, because of the inadequacy of degraded DNA from
paraffin-embedded tissues for such analyses.
Mutations of Ki-ras codon 12 were screened by mutant-
enriched PCR and characterized by allele-specific oligonucleotide
hybridization (ASO), according to Hruban et al (1993). Immuno-
histochemistry for p53 protein was performed on paraffin sections,
using pAbl801 monoclonal antibody (Scarpa et al, 1993).
Truncating mutations ofAPC gene were searched using the APC
protein truncation test (PTT) analysis of codons 654-1700, as
previously described in detail (Achille et al, 1996b). Mutations of
the p53 gene were investigated using single-strand conformation
polymorphism and direct DNA sequencing of PCR-amplified
DNA fragments (Scarpa et al, 1993).
Microsatellite instability was assessed through PCR amplifica-
tion of four loci, including DlS158, DXS538, MAOB and APA3.
LOH at specific chromosomal loci was examined by PCR amplifi-
cation of ten microsatellites. These included D5S82 and D5S299
for chromosome 5q21; D17S513, D17S1176 and D17S559 for
chromosome l7pl3; D18S65, D18S61 and D18S55 for chromo-
some 18q21; D3S1234 and D3S1300 for chromosome 3pl4. All
appropriate primers for amplification of microsatellites were
purchased from the MapPairs collection (Research Genetics,
Huntsville, AL, USA). They were used at the annealing tempera-
ture indicated by the manufacturer when using high-quality DNA
from frozen tissues and at 5°C lower when using DNA from
paraffin-embedded tissues. The PCR reaction (10,l) and product
detection for microsatellite instability and LOH studies were
performed as previously described in detail forhigh-quality DNAs
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Table 2 Detailed results of loss of heterozygosity by microsatellite analysisa
Case Chromosome 3p14 Chromosome 5q21 Chromosome 17p13 Chromosome 18q21
D3S1234 D3S1300 D5S82 D5S299 D17S513 D17S1176 D17S559 D18S65 D18S61 D18S55
DC 2 - No - - b b b _ _ No
DC 6 NI Not ampl. No No No No NI NI No No
DC 3 No NI Loss NI NI No No No No n.i.
DC 4 Not ampl. - NI No Not ampl. - - Not ampl. - -
DC 5 No No NI Loss NI Loss Loss No NI NI
DC 1 NI Loss NI Loss Loss NI Loss No NI No
DC 7 No Not ampl. Loss Loss Not ampl. NI NI NI Loss Loss
DC 8 Loss Loss NI No Loss Loss Loss No NI Not ampl.
DC 9 NI No Loss Loss NI Loss Loss Loss Loss Not ampl.
DC 10 No NI No NI Loss Loss NI NI Loss NI
DCl1 - - - Not ampl. - Notampl. - - Not ampl.
DC 12 No No Loss NI Loss Not ampl. NI No NI No
aNI, not informative; -, not evaluable for instability of all microsatellites analysed; not ampl. stands for no PCR amplification of either normal or tumour DNA.
bThe absence of 17p loss was demonstrated by Southern blot (see Results). Note that, of the three USM+ cancers, DC2 had two stable and informative loci,
DC4 had two stable but only one informative loci and for DC11 all locus were unstable.
(Achille et al, 1996a and b), with a modification for DNA from
paraffin-embedded tissues, consisting of the addition of five PCR
cycles. Microsatellite instability was defined when a shift and/or
gain of electrophoretic bands was detected (Kim et al, 1994),
whereas LOH was characterized by loss ofthe bands representing
one allele (Achille et al, 1996a).
The TGF-ORII gene was analysed by PCR amplification of the
73-bp (nucleotides 665-737) which contains the mutational hotspot
represented by a 10-bp polyadenine tract (codons 125-128)
(Markowitz et al, 1995; Myeroff et al, 1995; Parsons et al, 1995).
Genomic DNA (50 and 100 ng) was amplified in duplicate experi-
ments using forward [y-32P]ATP 5'-end-labelled primer TAIO-Fl
(5'-CTlITATTCTGGAAGATGCTGC-3') andreverseprimerTA1O-
RI (5'-GAAGAAAGTCTCACCAGG-3') (Myeroff et al, 1995).
PCR for both high-quality and partly degraded DNAs consisted of
30 cycles of 95°C for 30 s, 55°C for 60 s and 72°C for 60 s. The
PCRproducts wereelectrophoresed for 1 hat60 W in 6% polyacry-
lamide (5% cross-linker, 0.2 mm thick) gel containing 8 M urea and
were visualized by autoradiography. The standard in each assay was
established by amplifying the wild-type TGF-PRII gene from
plasmid H2-3FF (Lin et al, 1992), kindly provided by Professor RA
Weinberg (Whithead Institute, MIT, Cambridge, MA, USA).
RESULTS
The results ofthe molecular studies are summarized in Table 1, and
details ofchromosomal allelic losses are given in Table 2. We first
analysed the two cancers for which high-quality DNA from frozen
samples was available (DC1 and DC2). After testing the suitability
for genetic analysis of the partly degraded DNA from formalin-
fixed paraffin-embedded samples, as processed at our institution,
we extended the study to the additional ten cases ofour series.
Molecular analysis of cancers DC1 and DC2
Cancer DCI showed mutations in APC, Ki-ras and p53 genes,
together with allelic losses at chromosomal loci 5q21, 17pl3 and
3p14 (Figure 1). Chromosome 18q21 alleles were retained, and
neither microsatellite instability nor insertions or deletions in the
TGF-fRIIgene were found.
Cancer DC2 showed instability at all four microsatellites used
fordetection ofthis anomaly (Figure 2), and also in the majority of
the microsatellites (eight of ten) used for LOH analyses.
Therefore, it was classified as a USM+ neoplasm. TheTGF-PRII
gene of this cancer had a 1-bp deletion in both alleles within the
polyadenine tract. Such biallelic mutation predicts an inactive
truncated receptor protein of 161 amino acids (Myeroff et al,
1995). This case had neither APC, nor Ki-ras or p53 mutations.
The two microsatellites not showing instability, D3S1300 and
D18S55, were both informative and showed no allelic loss. The
absence of allelic losses at the 17pl3 locus was demonstrated by
Southem blot analysis of MspI-digested DNA hybridized to the
pYNZ22 probe (American Type Culture Collection, Rockville,
MD, USA) (data not shown).
Adequacy of paraffin-embedded samples and summary
of molecular anomalies
We assessed the adequacy offormalin-fixed and paraffin-embedded
tissue from our institution by testing the DNA extracted from
paraffin blocks of cancers DC1 and DC2 for Ki-ras and TGF-,RII
mutations, microsatellite instability and LOH at chromosomes 17p
and 18q (Figure 3). The results perfectly matched those obtained
with DNA from frozen tissues. We then extended the study to the
remaining ten cases, whose partly degraded DNA could be success-
fully tested for all the molecular anomalies analysed in cases DC1
and DC2, with the exception of APC and p53 gene mutations.
However, thedetectionofp53 protein accumulation incellnucleiby
immunohistochemistry serves as a surrogate forp53 gene mutations
in gastrointestinal cancers (Kim et al, 1994; Achille et al, 1996b).
In summary, Ki-ras codon 12 mutations were detected in 5 of
the 12 cancers (42%). They were GGT to GAT in four instances
and GGT to GCT in one. Abnormal accumulation ofp53 protein
was found in eight cancers (67%), all showing immunostaining in
the vast majority ofcancer cell nuclei. Six ofthese eight cases had
a complete loss ofp53 function, as suggested by the concomitant
loss ofthe normal p53 allele on chromosome 17p. Allelic losses at
chromosomes 3p, Sq, 17p and 18q were found in two of nine
(22%), six of ten (60%), six ofnine (67%) and three often (30%)
informative cancers, respectively. Three of the 12 cancers (25%)
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Figure 1 Case DC1. The microphotographs show the moderately
differentiated cancer DC1 (A) with p53 nuclear accumulation in the large
majority of cancer cell nuclei, demonstrated by immunohistochemistry (B). In
(C) is shown the analysis of PCR-amplified microsatellites D3S1300,
D5S299, D17S513 and D18S55, which are located at chromosomes 3p14,
5q21, 17p13 and 18q21, respectively. N and T identify normal and tumour
DNAs. This cancer has lost the upper allele of the D5S299 locus, and the
lower allele of the D3S1300 and Dl7S513 loci. Both 18q21 alleles are
retained. In (D) are displayed the gene mutations of this cancer. APC
mutations were tested by the protein truncation test on codons 1028-1700.
Lane N shows the 68.5-kDa product obtained from normal genes (normal
duodenal mucosa of the same patient), in which the additional bands visible
under the major product are due to either degradation or internal initiation of
translation. Lane DC1 contains a truncated product of about 40 kDa. Ki-ras
mutations were investigated by ASO hybridization. Case DC1 shows a GAT
allelic mutation, whereas case DC2 shows only a germline (GGT) signal; the
GTT mutation of a pancreatic cancer was used as control. The p53 sequence
shows a missense point mutation at codon 272 (va/to met)
Figure 2 Case DC2. The upper panel is a whole mount paraffin section
showing the duodenal cancer DC2, not involving the papilla of Vater; the
asterisk indicates the choledochus. In the lower panel, A, B and C,
respectively, correspond to the analysis of microsatellite instability by PCR
amplification of simple repeat loci DlSi 58 (CT ), DXS538 (AT8-AC15), and
MAOB (CT4-CA23-CA4) of paired normal (N) and tumour (T) DNAs. In this
case, the instability is represented by allelic shifts extending the normal allele
size by a variable number of base pairs ranging from 4 to more than 20. The
polyadenine tract of the TGF-,BRII gene shows a 1-bp deletion of both alleles
(T), compared with the wild type pattern (N). This experiment was conducted
in duplicate, using 100 ng of genomic DNA on the left N and T lanes, and
50 ng on the right N and T lanes
showed widespread microsatellite instability of the type seen in
USM+ cancers. Two ofthese three cancers (DC2 and DC4) showed
a l-bp deletion in the TGF-3RII gene, whereas all the other cases
scored negative. The occurrence ofchromosomal losses could not
be assessed in every locus of the three USM+ cancers, because of
the instability at the microsatellite loci tested (Table 2).
Finally, the adenomatous component of case DC1 was micro-
dissected and tested for selected genetic anomalies, including Ki-
ras mutations and LOH at 5q21, l7pl3 and 3pl4 chromosomal
loci. The results confirmed that the Ki-ras mutation was already
present at the adenoma stage, whereas 5q21 and 17pl3 LOH were
confined to the cancer tissue. In addition, p53 immunohisto-
chemistry showed that the p53 mutated protein was accumulated
in more than 90% ofcancer cell nuclei but not in adenoma cells.
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Figure 3 Analysis of allelic losses at chromosomes 17p and 18q (upper and
lower panels, respectively), using DNA from six formalin-fixed paraffin-
embedded duodenal cancers and PCR amplification of the microsatellite loci
indicated at the bottom of each panel. Case numbers are at the top of each
panel. T is the tumour and N the matched normal tissue DNA. Cases DC3
and DC5 show retention and loss of heterozygosity at chromosome 17p
locus D17S559, respectively, whereas both cases are not informative at
D18S55 locus. Cases DC9 and DC10 show the loss of either 17p or 18q loci.
Cases DC4 and DC1 1 are good examples of the possible findings in USM+
neoplasms, i.e. the disappearance of an allele with the comparison of a new
one, the presence of additional longer or shorter fragments and a
combination of these phenomena
DISCUSSION
Our study demonstrates that sporadic duodenal non-ampullary
cancers may arise through each of the two known molecular path-
ways recognized in gastric and colonic cancers. The majority of
our cases showed frequent chromosomal changes and mutations of
Ki-ras and p53 genes, while widespread subtle alterations due to
mismatch repair deficiency occurred in a minority.
Nine of the cases in our series may be considered to be cancers
with a 'tumour-suppressor' pathogenesis. They included one of the
two cancers confined to the duodenal wall, two of the three trans-
mural cancers and all but one cancer with nodal metastases. Ki-ras
mutations occurred in five of these cases (55%), whereas all but the
cancer confined to the duodenal submucosa (case DC6) showed p53
alterations (89%). The most frequent chromosomal losses were at Sq
and 17p, found in six of these nine cases (67%) and in six of eight
informative cases (75%) respectively. Ki-ras mutations were found
in cancers at different stages, also including one cancer confined to
the duodenal wall, whereasp53 and chromosome 17p and 18q alter-
ations were only associated with transmural and metastasizing
cancers. The small number of cases and the fact that most cancers
were already metastasizing made it difficult to reconstruct the timing
of the different molecular changes. However, some insight on their
sequential occurrence could be gained by the separate study of the
adenomatous and carcinomatous components of case DC1. In this
case, the mutations of Ki-ras, and possibly ofAPC, occurred at the
adenoma stage, whereas the p53 mutation occurred at the time
of carcinomatous transformation. The carcinomatous phase was
also characterized by the complete inactivation of APC and p53
functions, by the deletion of the chromosomal 5q21 and 17pl3 loci
containing their respective normal alleles. This scenario parallels that
of the common type sporadic colorectal cancer. Such similarity is
further supported by the fact that duodenal non-ampullary cancer
only occurs at high frequency in patients affected by FAP, in whom it
is the leading cause of death after colorectal cancer (Achille et al,
1996b). In this condition, it largely exceeds, in frequency, those orig-
inating from the structures of the papilla of Vater, and also shows
frequent somatic mutations in the adenomatous polyposis coli (APC)
gene, besides germline mutations (Achille et al, 1996b).
Three cases in our series (25%) were considered to be typical
USM+ tumours, showing widespread microsatellite instability, and
two of them also had a truncating mutation of the TGFP-RII gene.
These cases included one moderately differentiated, one colloid
and one poorly differentiated cancer, without evidence of Ki-ras or
p53 mutations. Gastric and colorectal USM+ cancers differ from
their USM- counterpart in that they frequently show poor differen-
tiation or colloid features, a low representation of p53 mutations
and a low frequency of lymph node metastasis (Lothe et al, 1993;
Kim et al, 1994; Dos Santos et al, 1996; Shibata, 1996). It is also
interesting that the three USM+ cancers in our study showed no
chromosomal losses at their few informative loci. This further
illustrates the similarity between duodenal USM+ cancers and
those observed in stomach and colon, which rarely show chromo-
somal losses (Aaltonen et al, 1993; Jen et al, 1994; Strickler et al,
1994; Shibata, 1996), at variance with the high frequency of losses
observed in USM- cancers. All three patients with USM+ duodenal
cancers, including two with local disease and one with a metasta-
sizing lesion, were long survivors with no evidence of disease.
This is again reminiscent of colorectal and gastric USM+ cancers,
which are usually diagnosed at a stage earlier than that of USM-
common cancers, and bear a good prognosis even in the presence
of nodal metastases (Thibodeau et al, 1993; Kim et al, 1994; Dos
Santos et al, 1996; Konishi et al, 1996). The observation that
patient DC11 was still alive more than 12 years from surgery,
together with the possibility of testing USM status on DNA from
paraffin-embedded material, should hopefully prompt researchers
with available larger series to test the several reported patients
with lymph node-positive duodenal cancers surviving for as long
as 9 years (Rose et al, 1996; Sexe et al, 1996).
We conclude that sporadic duodenal non-ampullary cancers
share similar molecular pathogenetic pathways to those of gastric
and colorectal cancers. The small number of cases available at our
institution does not allow the assessment ofthe prognostic value of
the molecular variables through a survival analysis. However, our
preliminary findings, if confirmed in a larger series, would suggest
that, at least, USM status may be used as a prognostic marker that
is as useful for patients with duodenal cancers as for those with
gastric and colorectal malignancies (Lothe et al, 1993; Thibodeau
et al, 1993; Jen et al, 1994; Kim et al, 1994; Dos Santos et al, 1996;
Konishi et al, 1996; Shibata, 1996).
ABBREVIATIONS
APC, adenomatous polyposis coli gene; FAP, familial adeno-
matous polyposis; HNPCC, hereditary non-polyposis colorectal
cancer; LOH, loss ofheterozygosity; PCR, polymerase chain reac-
tion; PTT, protein truncation test; RER, replication error; TGF-
PRII, transforming growth factor beta type II receptor; USM,
ubiquitous somatic mutations; USM+ and USM-, ubiquitous
somatic mutations positive and negative respectively
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